PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race
PatentVest Releases New Report on The Oral Small-Molecule GLP-1 Patent Race
PatentVest (Nasdaq: MDBH) released a PatentVest Pulse report, “The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron,” analyzing 1,200+ patent documents across 50 programs to assess patent depth and long-term exclusivity.
PatentVest (Nasdaq: MDBH) released a PatentVest Pulse report, “The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron,” analyzing 1,200+ patent documents across 50 programs to assess patent depth and long-term exclusivity.
Key findings: clinical efficacy converging at 12–16% weight loss, $71 billion injectable GLP-1 market, $47 billion in GLP-1 deal value since 2023, and looming patent cliffs for semaglutide (2031) and tirzepatide (2036).
Loading...
Loading translation...
Positive
1,200+ patent documents analyzed
50 oral small-molecule GLP-1 programs mapped
$47 billion in GLP-1 deal value committed since 2023
Clinical efficacy converging at 12–16% weight loss
Negative
Most oral programs remain unpartnered
Semaglutide patent cliff in 2031, tirzepatide cliff in 2036
Dramatic disparities in patent depth among similar-stage programs
In the Feb 26 session, MDBH declined 1.29%, reflecting a mild negative market reaction.
Data tracked by StockTitan Argus on the day of publication.
Market Context
This announcement highlights PatentVest’s latest deep-dive into oral small-molecule GLP-1 programs, ...
Analysis
This announcement highlights PatentVest’s latest deep-dive into oral small-molecule GLP-1 programs, mapping more than 1,200 patent documents across 26 clinical-stage assets in a $71 billion market. For MDBH, it reinforces the strategy of monetizing IP intelligence across large, competitive therapeutic areas. Recent history shows varied stock reactions to similar PatentVest reports, so investors may watch for follow-on mandates, partnerships, or transaction activity that tie this research more directly to MDBH’s financial results.
Key Figures
Injectable GLP-1 market size:$71 billionPatient penetration:<5% of eligible patientsOral GLP-1 programs:50 programs+5 more
Injectable GLP-1 market size
$71 billion
Market built by injectable GLP-1 drugs
Patient penetration
<5% of eligible patients
Share of eligible patients reached by injectable GLP-1s
Oral GLP-1 programs
50 programs
Oral small-molecule GLP-1 programs racing for market share
Weight-loss efficacy range
12–16% weight loss
Clinical efficacy across leading oral small-molecule GLP-1 programs
Patent documents analyzed
1,200+ documents
Patents reviewed in the GLP-1 report
Clinical-stage programs
26 programs
Clinical-stage oral small-molecule GLP-1 programs in IP review
PatentVest report on $133B cardiac diagnostics IP landscape.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
glp-1, composition-of-matter, markush, formulation, +1 more
5 terms
glp-1medical
"As injectable GLP-1 drugs built a $71 billion market while reaching less than 5%..."
GLP-1 (glucagon-like peptide-1) is a natural hormone in the body that helps regulate blood sugar levels and appetite. Its significance to investors lies in its role as the basis for a class of medications that address conditions like type 2 diabetes and obesity, which are large and growing markets. Advances or investments in GLP-1-based treatments can signal opportunities in healthcare innovation and potentially impact pharmaceutical companies’ growth.
A composition-of-matter is a legal description of a specific chemical or biological substance or mixture—think of it as the exact recipe and ingredients that make up a drug, material, or chemical product. For investors, ownership of a composition-of-matter patent can act like a locked recipe that keeps competitors out, protecting future sales and profit margins and reducing the risk that a product will be easily copied.
Markush is a style of patent claim that groups multiple chemical structures or ingredients under a single description, effectively saying a product can contain A or B or C (or combinations) without listing each variant separately. Think of it like a recipe that allows several substitute ingredients — it can make intellectual property broader and harder for rivals to design around, so investors watch Markush claims because they affect how long a product can be protected, its licensing value, and competitive risk.
formulationtechnical
"Markush scope, formulation layers, and method-of-use protection."
A formulation is the specific recipe and physical form that combines an active ingredient with other components to create a usable medicine, supplement, or product — for example a pill, injection, cream, or inhaler. Investors care because formulation determines how well a product works, how safe and easy it is to make and sell, and how long it can be protected or differentiated in the market; think of it as the finished vehicle that delivers the engine (the active ingredient) to its destination.
method-of-usetechnical
"formulation layers, and method-of-use protection."
A method-of-use is a legal description of how a medicine, medical device, or technology is intended to be used to treat a specific condition or achieve a particular result. Think of it as the recipe for applying a product rather than the product itself; it can be protected by patents or regulatory approvals. Investors watch method-of-use protections because they can extend exclusive rights, affect future sales, create licensing opportunities, or trigger litigation that changes a product's commercial value.
Analysis of 1,200+ patent documents reveal which programs are building durable exclusivity, and which may not be
Dallas, TX, Feb. 26, 2026 (GLOBE NEWSWIRE) -- PatentVest, the first fully integrated IP intelligence and strategy firm, has released its latest PatentVest Pulse report, “The Oral Small-Molecule GLP-1 Race: Beyond Orforglipron.”
As injectable GLP-1 drugs built a $71 billion market while reaching less than 5% of eligible patients, fifty oral small-molecule programs are now racing to unlock the remaining 95%. Clinical efficacy across leading programs is converging in the 12–16% weight-loss range.
In this increasingly competitive field, long-term differentiation depends not only on clinical performance but also on the strength and defensibility of each program’s patent portfolio.
The report reviews more than 1,200 patent documents across 26 clinical-stage programs, mapping composition-of-matter claims, Markush scope, formulation layers, and method-of-use protection. The findings reveal dramatic disparities in patent depth between programs at similar development stages.
More than $47 billion in GLP-1-related deal value has been committed since 2023, yet most oral programs remain unpartnered. With semaglutide’s patent cliff approaching in 2031 and tirzepatide’s in 2036, long-term exclusivity will determine which assets become franchises and which face early generic pressure.
“When multiple drugs deliver similar weight-loss results, the competitive moat shifts beneath the surface,” said Javier Chamorro, Chief Operating Officer of PatentVest. “The difference between a broad genus claim and a narrow composition patent can determine who owns this market for the next twenty years.”
This analysis maps 50 oral small-molecule GLP-1 programs worldwide, including 30 in clinical development, and evaluates the IP positioning of leading assets from Eli Lilly, Novo Nordisk, Pfizer, Roche, AstraZeneca, Gilead, Structure Therapeutics, and others.
This is the first in a series of deep-dive analyses evaluating the structural and patent defensibility of each major program.
PatentVest, a division of MDB Capital Holdings (Nasdaq: MDBH), is the first integrated IP intelligence, strategy, and law firm designed to help visionary companies become technology leaders. Powered by a proprietary global IP database and a rigorous diligence methodology, PatentVest delivers actionable intelligence that reveals the structural advantages hidden beneath technology markets.
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What does the PatentVest report say about the oral GLP-1 market opportunity for MDBH (MDBH)?
The report highlights a large unmet market: injectable GLP-1s built a $71 billion market while reaching under 5% of eligible patients. According to PatentVest, fifty oral programs are now racing to address the remaining patient opportunity and capture long-term share.
How many oral small-molecule GLP-1 programs and patents did PatentVest review in the Feb. 26, 2026 report?
PatentVest reviewed over 1,200 patent documents and mapped 50 oral programs worldwide. According to PatentVest, the analysis covered 26 clinical-stage programs and evaluated composition, formulation, and method-of-use protection.
What patent timelines in the PatentVest report could affect MDBH-listed assets (MDBH)?
The report flags key patent cliffs: semaglutide around 2031 and tirzepatide around 2036, which shape long-term exclusivity. According to PatentVest, these timelines increase the value of strong patent portfolios for franchise formation.
How does PatentVest assess clinical differentiation among oral GLP-1 candidates in the Feb. 26, 2026 report?
Clinical efficacy among leading oral programs is converging at 12–16% weight loss, reducing clinical separation. According to PatentVest, patent depth and claim breadth will therefore determine durable market differentiation.
What investor implications does the PatentVest Pulse report highlight for MDB Capital holdings (MDBH)?
The report implies IP strength will drive winner-take-most outcomes and partnership value in GLP-1 programs. According to PatentVest, investors should weigh patent breadth, partnership status, and patent cliffs when assessing program upside and risk.
